ACADIA Pharmaceuticals Inc. Days of Inventory on Hand

Days of Inventory on Hand of ACAD for past 10 years: annual, quarterly and twelve month trailing (TTM) including Days of Inventory on Hand growth rates and interactive chart.


Highlights and Quick Summary

  • Annual Days of Inventory on Hand for 2020 was 198.68 (a 34.12% increase from previous year)
  • Annual Days of Inventory on Hand for 2019 was 148.14 (a -16.22% decrease from previous year)
  • Annual Days of Inventory on Hand for 2018 was 176.82 (a 3.81% increase from previous year)
  • Twelve month Days of Inventory on Hand ending March 30, 2021 was 223.51 (a 10.62% increase compared to previous quarter)
  • Twelve month trailing Days of Inventory on Hand increased by 16.76% year-over-year
Trailing Days of Inventory on Hand for the last four month:
30 Mar '21 30 Dec '20 29 Sep '20 29 Jun '20
223.51 202.04 194.72 191.43
Visit stockrow.com/ACAD for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical Days of Inventory on Hand of ACADIA Pharmaceuticals Inc.

Most recent Days of Inventory on Handof ACAD including historical data for past 10 years.

Interactive Chart of Days of Inventory on Hand of ACADIA Pharmaceuticals Inc.

ACADIA Pharmaceuticals Inc. Days of Inventory on Hand for the past 10 Years (both Annual and Quarterly)

Year Q1 Q2 Q3 Q4 Fiscal Year
2020 198.68
2019 148.14
2018 176.82
2017 170.34
2016 103.27

Business Profile of ACADIA Pharmaceuticals Inc.

Sector: Healthcare
Industry: Biotechnology
ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; Trofinetide, a novel synthetic analog for the treatment of Rett syndrome; ACP-044, a novel first-in-class orally administered non-opioid analgesic for treating acute and chronic pain; and ACP-319, a positive allosteric modulator of the muscarinic receptor for treating cognition and schizophrenia. It is also developing pimavanserin as a treatment for dementia-related psychosis and as an adjunctive treatment for schizophrenia; and pimavanserin as an adjunctive treatment for major depressive disorder. ACADIA Pharmaceuticals Inc. was founded in 1993 and is headquartered in San Diego, California.